Puma Biotech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PUMA BIOTECH, and what generic alternatives to PUMA BIOTECH drugs are available?
PUMA BIOTECH has one approved drug.
There are ten US patents protecting PUMA BIOTECH drugs.
There are one hundred and forty-nine patent family members on PUMA BIOTECH drugs in thirty-one countries.
Drugs and US Patents for Puma Biotech
Expired US Patents for Puma Biotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | 6,288,082 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Puma Biotech Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Poland | 2498756 | See Plans and Pricing |
Japan | 2021100985 | See Plans and Pricing |
Singapore | 174382 | See Plans and Pricing |
Spain | 2561495 | See Plans and Pricing |
Canada | 2928071 | See Plans and Pricing |
Taiwan | 201138774 | See Plans and Pricing |
Japan | 5965640 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.